Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

Trial Profile

Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Febuxostat (Primary) ; Verinurad (Primary)
  • Indications Hyperuricaemia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top